摘要
肝细胞癌(HCC)是我国常见的恶性肿瘤,其中大部分患者有慢性乙型肝炎病毒(HBV)感染背景。核背(酸)类药物(NAs)是目前各大指南推荐的治疗慢性乙型肝炎的一线用药。然而,在临床上观察到部分接受NAs治疗且已经获得病毒学应答(HBV DNA低于检测下限)的患者仍可以进展为HCC,其发展机制尚不明确。现主要从病毒基因整合和持续的肝脏炎症损伤方面对NAs治疗下慢性乙型肝炎患者进展为HCC的相关机制进行分析。
Hepatocellular carcinoma(HCC)is a common malignant tumor in China,and most of the patients have a background of chronic HBV infection.Nucleos(t)ide drugs(NAs)are currently recommended by major guidelines as a first-line treatments for chronic hepatitis B.However,it is still clinically possible to observe that some patients who have acquired virological response(HBV DNA below the lower detection limit)after NAS treatment progress to HCC,and its mechanism of development is still unclear.In this review,the mechanism relevant to HCC progression in treatment of chronic hepatitis B patients with NAs is analyzed mainly from the aspects of gene integration and persistent inflammatory injury.
作者
高田敬
韩耕愚
鲁凤民
Gao Tianjing;Han Gengyu;Lu Fengmin(Peking University First Hospital,Beijing 100032,China;Peking University Third Hospital,Beijing 100191,China;Department of Microbiology,School of Basic Medical Sciences,Peking University Health Science Center,Beijing 100191,China)
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2019年第11期905-909,共5页
Chinese Journal of Hepatology
基金
“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项基金资助项目(2017ZX10302201)。
关键词
肝炎病毒
乙型
癌
肝细胞
核苷(酸)类药物
基因整合
炎症损伤
Hepatitis B virus
Carcinoma
hepatocellular
Nucleoside analogs
Gene integration
Inflammatory damage
